Chemotherapy for Lung Cancer
Author:
Publisher
Springer Berlin Heidelberg
Link
https://link.springer.com/content/pdf/10.1007/174_2022_311
Reference148 articles.
1. Adrianzen Herrera D, Ashai N, Perez-Soler R, Cheng H (2019) Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother 20(1):95–102
2. Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA et al (2020) Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clin Cancer Res 26(10):2354–2361
3. Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR (2021) Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol 18(1):56–62
4. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (London, England) 374(9687):379–386
5. Alexander M, Ko B, Lambert R, Gadgeel S, Halmos B (2020) The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Rev Respir Med 14(2):137–147
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3